NovoCure LimitedNVCR stock score: 44/100

$10.69 · -0.37% · Scored Nov 19, 2026

Technical
23
Fundamental
50
News
—

The reading

NovoCure (NVCR) scores 44 out of 100, which reads weak, higher than 34% of Healthcare stocks and 32% of the 4,118 US stocks we score.

The composite weights fundamentals 80% and technicals 20%: fundamentals read 50, technicals 23.

Among the fundamentals, Price Target at 100 and Revenue Quality (Quarterly) at 100 score highest, while Earnings Growth (5-Year) at 0 weighs the most against it.

On the daily chart, trend-following indicators average 10 and contrarian oscillators 71 — a split worth reading before trusting the technical total.

Since Aug 22, 2026 the composite has ranged from 33 to 48, and it is down 2 points over the period.

About NovoCure

NovoCure (NVCR) is an oncology company that sells Tumor Treating Fields, a therapy that uses alternating electric fields delivered through arrays placed on the skin to disrupt cancer cell division. Patients wear the portable device for most of the day at home. Its products include Optune Gio for glioblastoma, an aggressive brain cancer, Optune Lua for non-small cell lung cancer and pleural mesothelioma, and Optune Pax for locally advanced pancreatic cancer, approved for use alongside chemotherapy. NovoCure sells mainly in the United States, Germany and Japan, along with other countries in Europe and Asia. It earns money mainly by billing insurers and government health programs a monthly fee for each patient on therapy, which covers the device, arrays and support services.

NovoCure’s therapy is used alongside chemotherapy, radiation and immunotherapy rather than replacing them, and it competes for patients and payer budgets with cancer drugs from companies such as Merck, AstraZeneca and Roche. Its edge rests on being the only company with approved Tumor Treating Fields products, along with patents and data from several late-stage trials. Investors who follow NVCR stock tend to watch active patients on therapy and new prescriptions. Uptake of Optune Lua and Optune Pax is closely followed. Reimbursement decisions, results from ongoing trials, gross margins, operating costs and convertible debt are other factors.

What’s driving the score

The strongest and weakest of the scorers that count toward NVCR’s composite. Each returns 0–100, higher is more bullish — including metrics where low is good, like P/E.

Fundamental

50

Pulling it up

  • Price target score compares the current stock price to analyst consensus targets.

  • How the latest quarter's revenue compares with the average of the last four, plus a bonus for steady quarterly revenue.

  • EV/Revenue compares the whole company's value, debt included, with its sales.

Holding it back

38 weighted scorers; 1 had no data today and are left out rather than counted as zero.

Technical · daily

19

Pulling it up

  • Bollinger Bands (50-period) measure where price sits between bands two standard deviations around its 50-period average.

  • Relative Strength Index (14-period) measures momentum by comparing recent gains to losses.

  • Bollinger Bands (20-period) plot standard deviations above and below a moving average.

Holding it back

  • Performance versus SPY compares the stock's returns to the S&P 500 index.

  • Ichimoku Cloud is a comprehensive indicator showing support/resistance, trend direction, and momentum.

  • Simple Moving Average (100-period) provides a longer-term perspective on price trends.

61 weighted scorers; 4 had no data today and are left out rather than counted as zero.

Technical score by timeframe

ChartScoreWeight
Hourly321
Daily193
Weekly192
Monthly292

Composite score, last 90 days

05010044Aug 22, 2026Nov 19, 2026Aug 22, 2026: 46Aug 23, 2026: 47Aug 24, 2026: 45Aug 25, 2026: 47Aug 26, 2026: 48Aug 27, 2026: 47Aug 28, 2026: 46Aug 29, 2026: 47Aug 30, 2026: 47Aug 31, 2026: 46Sep 1, 2026: 46Sep 2, 2026: 47Sep 3, 2026: 46Sep 4, 2026: 46Sep 5, 2026: 47Sep 6, 2026: 47Sep 7, 2026: 47Sep 8, 2026: 44Sep 9, 2026: 40Sep 10, 2026: 39Sep 11, 2026: 40Sep 12, 2026: 39Sep 13, 2026: 39Sep 14, 2026: 41Sep 15, 2026: 41Sep 16, 2026: 41Sep 17, 2026: 43Sep 18, 2026: 44Sep 19, 2026: 43Sep 20, 2026: 43Sep 21, 2026: 42Sep 22, 2026: 44Sep 23, 2026: 42Sep 24, 2026: 42Sep 25, 2026: 40Sep 26, 2026: 39Sep 27, 2026: 39Sep 28, 2026: 38Sep 29, 2026: 40Sep 30, 2026: 40Oct 1, 2026: 40Oct 2, 2026: 38Oct 3, 2026: 37Oct 4, 2026: 37Oct 5, 2026: 37Oct 6, 2026: 38Oct 7, 2026: 36Oct 8, 2026: 35Oct 9, 2026: 36Oct 10, 2026: 37Oct 11, 2026: 37Oct 12, 2026: 37Oct 13, 2026: 36Oct 14, 2026: 35Oct 15, 2026: 36Oct 16, 2026: 35Oct 17, 2026: 35Oct 18, 2026: 35Oct 19, 2026: 38Oct 20, 2026: 41Oct 21, 2026: 42Oct 22, 2026: 40Oct 23, 2026: 37Oct 24, 2026: 37Oct 25, 2026: 37Oct 26, 2026: 36Oct 27, 2026: 37Oct 28, 2026: 36Oct 29, 2026: 34Oct 30, 2026: 34Nov 1, 2026: 35Nov 2, 2026: 35Nov 3, 2026: 36Nov 4, 2026: 40Nov 5, 2026: 37Nov 6, 2026: 34Nov 7, 2026: 35Nov 8, 2026: 35Nov 10, 2026: 33Nov 11, 2026: 33Nov 12, 2026: 43Nov 13, 2026: 45Nov 14, 2026: 46Nov 15, 2026: 46Nov 16, 2026: 45Nov 17, 2026: 45Nov 18, 2026: 45Nov 19, 2026: 44
Show the daily numbers
DateComposite
Nov 19, 202644
Nov 18, 202645
Nov 17, 202645
Nov 16, 202645
Nov 15, 202646
Nov 14, 202646
Nov 13, 202645
Nov 12, 202643
Nov 11, 202633
Nov 10, 202633
Nov 8, 202635
Nov 7, 202635
Nov 6, 202634
Nov 5, 202637
Nov 4, 202640
Nov 3, 202636
Nov 2, 202635
Nov 1, 202635
Oct 30, 202634
Oct 29, 202634
Oct 28, 202636
Oct 27, 202637
Oct 26, 202636
Oct 25, 202637
Oct 24, 202637
Oct 23, 202637
Oct 22, 202640
Oct 21, 202642
Oct 20, 202641
Oct 19, 202638
Oct 18, 202635
Oct 17, 202635
Oct 16, 202635
Oct 15, 202636
Oct 14, 202635
Oct 13, 202636
Oct 12, 202637
Oct 11, 202637
Oct 10, 202637
Oct 9, 202636
Oct 8, 202635
Oct 7, 202636
Oct 6, 202638
Oct 5, 202637
Oct 4, 202637
Oct 3, 202637
Oct 2, 202638
Oct 1, 202640
Sep 30, 202640
Sep 29, 202640
Sep 28, 202638
Sep 27, 202639
Sep 26, 202639
Sep 25, 202640
Sep 24, 202642
Sep 23, 202642
Sep 22, 202644
Sep 21, 202642
Sep 20, 202643
Sep 19, 202643
Sep 18, 202644
Sep 17, 202643
Sep 16, 202641
Sep 15, 202641
Sep 14, 202641
Sep 13, 202639
Sep 12, 202639
Sep 11, 202640
Sep 10, 202639
Sep 9, 202640
Sep 8, 202644
Sep 7, 202647
Sep 6, 202647
Sep 5, 202647
Sep 4, 202646
Sep 3, 202646
Sep 2, 202647
Sep 1, 202646
Aug 31, 202646
Aug 30, 202647
Aug 29, 202647
Aug 28, 202646
Aug 27, 202647
Aug 26, 202648
Aug 25, 202647
Aug 24, 202645
Aug 23, 202647
Aug 22, 202646

Key facts

Market cap
$1.2B
Sector
Healthcare
Industry
Medical Devices
Beta
1.08
Risk grade (1–10)
4
Next earnings
Oct 29, 2026

Questions

What is NVCR's stock rating today?

NVCR scores 44/100 (Weak) as of Nov 19, 2026: technical 23, fundamental 50. Scores are recomputed every night.

What does NovoCure do?

NovoCure (NVCR) is an oncology company that sells Tumor Treating Fields, a therapy that uses alternating electric fields delivered through arrays placed on the skin to disrupt cancer cell division. Patients wear the portable device for most of the day at home.

Is NVCR stock a buy?

The score is not a buy or sell recommendation. A 44 says the technical and fundamental signals we measure lean weak today, relative to every other stock scored the same way. Use the breakdown above to see why, and treat it as a starting point for your own research.

How is the NVCR score calculated?

99 weighted scorers feed it today: 38 fundamental, scored against Healthcare ranges, and 61 technical on the daily chart, with 4 timeframes blended into the technical total. Every scorer returns 0–100; missing data is left out, never counted as zero.

Scores are information, not investment advice. Computed from Yahoo Finance, Finnhub and Alpha Vantage data; technical indicators via TA-Lib. Past scores do not predict future returns.

Embed this score

A badge for a blog post, newsletter or README. It updates every night and links back here. More badges

NVCR stock score

HTML

<a href="https://stocksscores.com/stocks/nvcr/"><img src="https://stocksscores.com/stocks/nvcr/badge.svg" alt="NVCR stock score" height="20"></a>

Markdown

[![NVCR stock score](https://stocksscores.com/stocks/nvcr/badge.svg)](https://stocksscores.com/stocks/nvcr/)